CD4 helper T cell epitope fusion peptide and vaccines thereof

Abstract

The invention provides CD4 helper T cell epitope fusion peptide, coding nucleic acid of the CD4 helper T cell epitope fusion peptide and an immune composition containing the CD4 helper T cell epitopefusion peptide. The epitope fusion peptide comprises cytomegalovirus epitope and influenza virus epitope. The epitope fusion peptide can greatly improve the cellular immune response level of target immunogens, especially weak immunogens, is an effective means for overcoming the immune tolerance of an immune system to antigens, especially tumor antigens or infection-related antigens, and is suitable for effectively enhancing the efficacy of vaccines.

Description

technical field [0001] The present invention belongs to the fields of molecular biology and immunology. Specifically, the present invention relates to a CD4 helper T cell epitope fusion peptide, especially relates to a vaccine containing the epitope fusion peptide and its application. Background technique [0002] T helper cells (Th cells) are a type of T cell that play an important role in the immune system, especially in the adaptive immune system. They aid the activity of other immune cells by releasing T-cell cytokines. These cells help suppress or regulate immune responses. They are essential in the switching of B cell antibody classes, the activation and growth of cytotoxic T cells, and in maximizing the bactericidal activity of phagocytes such as macrophages. [0003] Mature Th cells express the protein CD4, known as CD4 + T cells. Usually such CD4 + T cells undergo a predefined process as helper T cells within the immune system. For example, when antigen prese...

AI Technical Summary

Problems solved by technology

Therefore, when a subject is vaccinated with the above-mentioned strong Th epitopes, it is likely that the immune system of the vaccine subject is exposed to such Th epitopes for the first time, and the immune system of the recipient is activated against such Th epitopes and the target The epitopes of the immunogen are basically synchronized, and the generation time and number of T cells targeting such Th epitopes are similar to the target immunogen, so the effect on helping the target immunogen is thus limited

Especially for weakly immunogenic tumor antigens, it is more difficult for such Th epitopes to play a supporting role

In fact, although the direct use of strong Th epitopes can activate tumor antigens, the level of cellular immune response it stimulates is still low, which cannot meet the needs of tumor vaccines (Ghaffari-Nazari H et al., PLoS ONE, 2015, 10(11 ):e0142563)

Images